In DLBCL outside the CNS, TP53 mutations (MUT-TP53) have mostly been studied with emphasis on the disruption of the coding sequences of the DNA binding domain (DBD) (exons 5–8) with a reported mutation frequency of ~20–25 % [35, 52]. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.